The level of these molecules in the blood is linked to cognitive decline in people who have not yet received a diagnosis.
Once the diagnosis is made, it is too late to reverse Alzheimer’s disease. That is why identifying the earliest signs of cognitive decline is crucial. A team from Université Laval examined blood-based biomarkers and identified two promising molecules, according to a study published in Alzheimer’s & Dementia.
Exploring the metabolic pathway
The scientists studied molecules associated with metabolic diseases, such as type 2 diabetes or hypertension, which are linked to a higher risk of developing Alzheimer’s disease. “We wanted to see how these metabolic biomarkers behaved in relation to cognitive changes,” explains Frédéric Calon, explains professor at the Faculty of Pharmacy and researcher at the Centre de recherche du CHU de Québec – Université Laval, who led the study
read the article: Ulaval Nouvelles
